http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0f9d2379f959f2dfd9b70a55d1c2b32
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Ebi |
| name | Hiromichi Ebi |
| given-name | Hiromichi |
| organization-name | Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa 920-0934, Japan; Institute for Frontier Science Initiative, Kanazawa University, Ishikawa 920-1192, Japan Aichi Cancer Center, Nagoya, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan 4Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan. Division of Medical Oncology Cancer Research Institute Kanazawa University Kanazawa Ishikawa Japan Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan Division of Hematology/Oncology, National Cancer Center Hospital East. 1Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan.; 3Institute for Frontier Science Initiative, Kanazawa University, Ishikawa, Japan. Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School; 3Division of Gastroenterology, Department of Medicine, Tufts Medical Center; 4Department of Pathology, Massachusetts General Hospital, Boston; and 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School; 3Division of Gastroenterology, Department of Medicine, Tufts Medical Center; 4Department of Pathology, Massachusetts General Hospital, Boston; and 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts Massachusetts General Hospital Cancer Center, Boston, MA 02129;; Department of Medicine, Harvard Medical School, Boston, MA 02115; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute , Aichi , Japan Division of Molecular Therapeutics Aichi Cancer Center Research Institute Nagoya Japan; Division of Advanced Cancer Therapeutics Nagoya University Graduate School of Medicine Nagoya Japan Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan; Precision Medicine Center, Aichi Cancer Center, Nagoya, Japan; Division of Advanced Cancer Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan 1Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine;; 2Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences; and Divisions of Authors' Affiliations: 1Massachusetts General Hospital Cancer Center, 2Department of Medicine, Harvard Medical School, 3Division of Gastro-enterology, Tufts Medical Center, and Departments of 4Pathology and 5Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and 6Genentech, Inc., South San Francisco, California; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center, 2Department of Medicine, Harvard Medical School, 3Division of Gastro-enterology, Tufts Medical Center, and Departments of 4Pathology and 5Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and 6Genentech, Inc., South San Francisco, California Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan; Institute for Frontier Science Initiative, Kanazawa University, Ishikawa, Japan Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan Division of Medical Oncology Cancer Research Institute Kanazawa University Ishikawa Japan Authors' Affiliations: 1Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa; 2Department of Respiratory Medicine, Nagoya University; 3Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Aichi; and 4Tsukuba Research Laboratories, Eisai Co., ltd., Ibaraki, Japan Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129; and; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa 920-0934, Japan 1Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, and Authors' Affiliations: 1Pathology and 2Radiology, Massachusetts General Hospital, Boston; 3Massachusetts General Hospital Cancer Center, Boston; 4Department of Medicine, Harvard Medical School, Boston; 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; 6Department of Medicine, 7Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; 8Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú; Authors' Affiliations: 1Pathology and 2Radiology, Massachusetts General Hospital, Boston; 3Massachusetts General Hospital Cancer Center, Boston; 4Department of Medicine, Harvard Medical School, Boston; 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; 6Department of Medicine, 7Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; 8Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú Department of Medical Oncology, Kanazawa University Cancer Research Institute, Kanazawa, Japan Division of Molecular Therapeutics Aichi Cancer Centre Research Institute Aichi Japan; Precision Medicine Centre Aichi Cancer Centre Aichi Japan; Division of Advanced Cancer Therapeutics Nagoya University Graduate School of Medicine Nagoya Japan Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan 1Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer and Authors' Affiliations: 1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; 3Belfer Institute for Applied Cancer Science; 4Ludwig Center at Dana-Farber/Harvard Cancer Center; 5Massachusetts General Hospital Cancer Center; 6Department of Medicine, Harvard Medical School; 7Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 8Shanghai Jiaotong University School of Medicine, Shanghai, China; and 9Department of Molecular Pharmacology and Therapeutics, Oncology Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois; Authors' Affiliations: 1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; 3Belfer Institute for Applied Cancer Science; 4Ludwig Center at Dana-Farber/Harvard Cancer Center; 5Massachusetts General Hospital Cancer Center; 6Department of Medicine, Harvard Medical School; 7Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 8Shanghai Jiaotong University School of Medicine, Shanghai, China; and 9Department of Molecular Pharmacology and Therapeutics, Oncology Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois |
Incoming Links
Total number of triples: 80.